Claims
- 1. A compound of formula I
- 2. The compound according to claim 1 wherein W is SO2.
- 3. The compound according to claim 1 wherein X is O.
- 4. The compound according to claim 2 wherein Q is an optionally substituted 3-pyrrolidinyl group.
- 5. The compound according to claim 4 wherein X is O and R10 is an optionally substituted aryl or heteroaryl group.
- 6. The compound according to claim 5 wherein Y is CR12.
- 7. The compound according to claim 6 wherein Z is N.
- 8. The compound according to claim 6 selected from the group consisting of:
1-(phenylsulfonyl)-4-(3-pyrrolidinyloxy)-1H-indole; 4-(3-pyrrolidinyloxy)l-(thien-2-ylsulfonyl)-1H-indole; 4-{[4-(3-pyrrolidinyloxy)-1H-indol-1-yl]sulfonyl}aniline; 1-(1-naphthylsulfonyl)-4-(3-pyrrolidinyloxy)-1H-indole; 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-(3-pyrrolidinyloxy)-1H-indole; 1-(phenylsulfonyl)-4-(3-pyrrolidinyloxy)-1H-indazole; 1-(1-naphthylsulfonyl)-4-(3-pyrrolidinyloxy)-1H-indazole; 1-[(2-chlorophenyl)sulfonyl]-4-(3-pyrrolidinyloxy)-1H-indazole; 1-[(2-fluorophenyl)sulfonyl]-4-(3-pyrrolidinyloxy)-1H-indazole; 1-[3,4-dimethoxyphenyl)sulfonyl]-4-(3-pyrrolidinyloxy)-1H-indazole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-(3-pyrrolidinyloxy)-1H-indazole; N-(2-chloro-4-{[4-(3-pyrrolidinyloxy)-1H-indazol-1-yl]sulfonyl}phenyl)acetamide; N-(4-{[4-(3-pyrrolidinyloxy)-1H-indazol-ly}]sulfonyl)-phenyl)acetamide; 8-{[4-(3-pyrrolidinyloxy)-1H-indazol-1-yl]sulfonyl}-quinoline; 1-(1-naphthylsulfonyl)-4-(piperidin-4-yloxy)-1H-indazole; 1-(1-naphthylsulfonyl)-4-(piperidin-3-yloxy)-1H-indazole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-4-yloxy)-1H-indazole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-3-yloxy)-1H-indazole; 1-(phenylsulfonyl)-4-(piperidin-3-yloxy)-1H-indole; 4-{[4-(piperidin-3-yloxy)-1H-indol-1-yl]sulfonyl}aniline; 1-(1-naphthylsulfonyl)-4-(piperidin-3-yloxy)-1H-indole; 1-(phenylsulfonyl)-4-(piperidin-4-yloxy)-1H-indole; 4-{[4-(piperidin-4-yloxy)-1H-indol-1-yl]sulfonyl}aniline; 1-(1-naphthylsulfonyl)-4-(piperidin-4-yloxy)-1H-indole; 1-(phenylsulfonyl)-5-(pyrrolidin-3-yloxy)-1H-indole; 1-(phenylsulfonyl)-6-(pyrrolidin-3-yloxy)-1H-indole; 1-(phenylsulfonyl)-6-(pyrrolidin-3-yloxy)-1H-indazole; 1-(phenylsulfonyl)-5-(pyrrolidin-3-yloxy)-1H-indazole; the stereoisomers thereof; and the pharmaceutically acceptable salts thereof.
- 9. A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I
- 10. The method according to claim 9 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.
- 11. The method according to claim 9 wherein said disorder is schizophrenia or depression.
- 12. The method according to claim 10 wherein said disorder is Alzheimer's disease or Parkinson's disease.
- 13. The method according to claim 10 wherein said disorder is attention deficit disorder.
- 14. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
- 15. The composition according to claim 14 having a formula I compound wherein W is SO2.
- 16. The composition according to claim 14 having a formula I compound wherein X is O.
- 17. The composition according to claim 15 having a formula I compound wherein Y is CR12.
- 18. The composition according to claim 17 having a formula I compound wherein X is O; Q is an optionally substituted 3-pyrrolidinyl group and R10 is an optionally substituted aryl or heteroaryl group.
- 19. The composition according to claim 18 having a formula I compound selected from the group consisting of:
1-(phenylsulfonyl)-4-(3-pyrrolidinyloxy)-1H-indole; 4-(3-pyrrolidinyloxy)l-(thien-2-ylsulfonyl)-1H-indole; 4-{[4-(3-pyrrolidinyloxy)-1H-indol-1-yl]sulfonyl}aniline; 1-(1-naphthylsulfonyl)-4-(3-pyrrolidinyloxy)-1H-indole; 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-(3-pyrrolidinyloxy)-1H-indole; 1-(phenylsulfonyl)-4-(3-pyrrolidinyloxy)-1H-indazole; 1-(1-naphthylsulfonyl)-4-(3-pyrrolidinyloxy)-1H-indazole; 1-[(2-chlorophenyl)sulfonyl]-4-(3-pyrrolidinyloxy)-1H-indazole; 1-[(2-fluorophenyl)sulfonyl]-4-(3-pyrrolidinyloxy)-1H-indazole; 1-[3,4-dimethoxyphenyl)sulfonyl]-4-(3-pyrrolidinyloxy)-1H-indazole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-(3-pyrrolidinyloxy)-1H-indazole; N-(2-chloro-4-{[4-(3-pyrrolidinyloxy)-1H-indazol-1-yl]sulfonyl}phenyl)acetamide; N-(4-{[4-(3-pyrrolidinyloxy)-1H-indazol-ly}]sulfonyl)-phenyl)acetamide; 8-{[4-(3-pyrrolidinyloxy)-lH-indazol-1-yl]sulfonyl}-quinoline; 1-(1-naphthylsulfonyl)-4-(piperidin-4-yloxy)-1H-indazole; 1-(1-naphthylsulfonyl)-4-(piperidin-3-yloxy)-1H-indazole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-4-yloxy)-1H-indazole; 1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-3-yloxy)-1H-indazole; 1-(phenylsulfonyl)-4-(piperidin-3-yloxy)-1H-indole; 4-{[4-(piperidin-3-yloxy)-1H-indol-1-yl]sulfonyl}aniline; 1-(1-naphthylsulfonyl)-4-(piperidin-3-yloxy)-1H-indole; 1-(phenylsulfonyl)-4-(piperidin-4-yloxy)-1H-indole; 4-{[4-(piperidin-4-yloxy)-1H-indol-1-yl]sulfonyl}aniline; 1-(1-naphthylsulfonyl)-4-(piperidin-4-yloxy)-1H-indole; 1-(phenylsulfonyl)-5-(pyrrolidin-3-yloxy)-1H-indole; 1-(phenylsulfonyl)-6-(pyrrolidin-3-yloxy)-1H-indole; 1-(phenylsulfonyl)-6-(pyrrolidin-3-yloxy)-1H-indazole; 1-(phenylsulfonyl)-5-(pyrrolidin-3-yloxy)-1H-indazole; the stereoisomers thereof; and the pharmaceutically acceptable salts thereof.
- 20. A method for the preparation of a compound of formula Ie
Parent Case Info
[0001] This application claims priority from copending application serial No. 60/285,643, filed on Apr. 20, 2001, the entire disclosure of which is incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60285643 |
Apr 2001 |
US |